395 related articles for article (PubMed ID: 22801672)
21. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
[TBL] [Abstract][Full Text] [Related]
22. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
Laguno M; Blanch J; Murillas J; Blanco JL; León A; Lonca M; Larrousse M; Biglia A; Martinez E; García F; Miró JM; de Pablo J; Gatell JM; Mallolas J
Antivir Ther; 2004 Dec; 9(6):905-9. PubMed ID: 15651749
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.
von Knorring AL; Olsson GI; Thomsen PH; Lemming OM; Hultén A
J Clin Psychopharmacol; 2006 Jun; 26(3):311-5. PubMed ID: 16702897
[TBL] [Abstract][Full Text] [Related]
24. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.
Angermann CE; Gelbrich G; Störk S; Gunold H; Edelmann F; Wachter R; Schunkert H; Graf T; Kindermann I; Haass M; Blankenberg S; Pankuweit S; Prettin C; Gottwik M; Böhm M; Faller H; Deckert J; Ertl G;
JAMA; 2016 Jun; 315(24):2683-93. PubMed ID: 27367876
[TBL] [Abstract][Full Text] [Related]
25. [Benefits of a preventive psychiatric accompaniment in patients Hepatitis C Virus seropositive (HCV): prospective study concerning 39 patients].
Lang JP; Meyer N; Doffoel M
Encephale; 2003; 29(4 Pt 1):362-5. PubMed ID: 14615706
[TBL] [Abstract][Full Text] [Related]
26. Escitalopram in the treatment of anxiety symptoms associated with depression.
Bandelow B; Andersen HF; Dolberg OT
Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
[TBL] [Abstract][Full Text] [Related]
27. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
28. Superiority of escitalopram to paroxetine in the treatment of depression.
Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
[TBL] [Abstract][Full Text] [Related]
29. Specific serotonin reuptake inhibitors prevent interferon-α-induced depression in patients with hepatitis C: a meta-analysis.
Jiang HY; Deng M; Zhang YH; Chen HZ; Chen Q; Ruan B
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1452-60.e3. PubMed ID: 23648373
[TBL] [Abstract][Full Text] [Related]
30. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Bech P; Andersen HF; Wade A
Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-Gélinier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
32. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
Brown ES; Howard C; Khan DA; Carmody TJ
Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
[TBL] [Abstract][Full Text] [Related]
33. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
Favré P
Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
[TBL] [Abstract][Full Text] [Related]
34. [Escitalopram for intervention of psychiatric adverse events during peginterferon-alfa-2a and ribavirin treatment for chronic hepatitis C].
Qi M; Zhou B; Su M; Pan J; Zhang H
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jul; 33(7):1012-6. PubMed ID: 23895843
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.
Morasco BJ; Rifai MA; Loftis JM; Indest DW; Moles JK; Hauser P
J Affect Disord; 2007 Nov; 103(1-3):83-90. PubMed ID: 17292481
[TBL] [Abstract][Full Text] [Related]
36. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
Olié JP; Tonnoir B; Ménard F; Galinowski A
Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
[TBL] [Abstract][Full Text] [Related]
37. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C.
de Knegt RJ; Bezemer G; Van Gool AR; Drenth JP; Hansen BE; Droogleever Fortuyn HA; Weegink CJ; Hengeveld MW; Janssen HL
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1306-17. PubMed ID: 21999489
[TBL] [Abstract][Full Text] [Related]
38. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
[TBL] [Abstract][Full Text] [Related]
39. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
[TBL] [Abstract][Full Text] [Related]
40. Escitalopram for the prevention of peginterferon-α2a-associated depression.
Schaefer M; Berg T; Sarkar S; Neumann K
Ann Intern Med; 2013 Jan; 158(2):140. PubMed ID: 23318324
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
